{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:44:22Z","timestamp":1778885062270,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing clinical trials, more advantages over other non-selective pan-HDAC inhibitors are foreseeable. As it is of paramount importance to understand the complex regulatory web of mutual interactions involving epigenetic machinery and non-coding genome in regulating gene expression, herein, we investigated the intriguing interactions between HDAC6-induced lncRNA (LINC00152) and its possible sponge miRNA (hsa-miR-499a-5p) in multiple myeloma.<\/jats:p>","DOI":"10.1186\/s12920-023-01724-3","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T16:03:45Z","timestamp":1700237025000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment"],"prefix":"10.1186","volume":"16","author":[{"given":"Jingjing","family":"Pu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo G. H.","family":"Schmidt-Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"issue":"1","key":"1724_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-022-00975-3","volume":"7","author":"B Chen","year":"2022","unstructured":"Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther. 2022;7(1):121. https:\/\/doi.org\/10.1038\/s41392-022-00975-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"1724_CR2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2019.10.017","volume":"179","author":"FJ Slack","year":"2019","unstructured":"Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in Oncology. Cell. 2019;179(5):1033\u201355. https:\/\/doi.org\/10.1016\/j.cell.2019.10.017.","journal-title":"Cell"},{"issue":"1","key":"1724_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13046-022-02257-w","volume":"41","author":"AC Wu","year":"2022","unstructured":"Wu AC, Yang WB, Chang KY, Lee JS, Liou JP, Su RY, Cheng SM, Hwang DY, Kikkawa U, Hsu TI, Wang CY, Chang WC, Chen PY, Chuang JY. HDAC6 involves in regulating the lncRNA-microRNA-mRNA network to promote the proliferation of glioblastoma cells. J Exp Clin Cancer Res. 2022;41(1):47. https:\/\/doi.org\/10.1186\/s13046-022-02257-w.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1724_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/1574892815666200217125419","volume":"15","author":"X He","year":"2020","unstructured":"He X, Li Z, Zhuo XT, Hui Z, Xie T, Ye XY. Novel selective histone deacetylase 6 (HDAC6) inhibitors: a patent review (2016\u20132019). Recent Pat Anticancer Drug Discov. 2020;15(1):32\u201348. https:\/\/doi.org\/10.2174\/1574892815666200217125419.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"1724_CR5","doi-asserted-by":"publisher","unstructured":"Li SD, Zhao CL, Zhang GZ, Xu QF, Liu Q, Zhao W, Chou CJ, Zhang YJ. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple Myeloma activity. Bioorg Chem 2021 Nov:116:105278. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105278.","DOI":"10.1016\/j.bioorg.2021.105278"},{"key":"1724_CR6","doi-asserted-by":"publisher","unstructured":"Liu LF, Zhang LY, Chen XX, Yang K, Cui H, Qian R, Zhao SS, Wang LQ, Su XL, Zhao MY, Wang MZ, Hu Z, Lu T, Zhu Y, Zhou QQ, Yao YQ. Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for Multiple Myeloma. Eur J Med Chem 2023 Sep 25:261115833. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115833.","DOI":"10.1016\/j.ejmech.2023.115833"},{"key":"1724_CR7","doi-asserted-by":"publisher","first-page":"1157366","DOI":"10.3389\/fonc.2023.1157366","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, Sharma A, Ge F, Chen P, Yang Y, Liu H, Liu H, Zhao C, Mittal L, Asthana S, Schmidt-Wolf IGH. Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells. Front Oncol. 2023;13:1157366. https:\/\/doi.org\/10.3389\/fonc.2023.1157366.","journal-title":"Front Oncol"},{"issue":"5","key":"1724_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3390\/ijms18050945","volume":"18","author":"D Stephan","year":"2017","unstructured":"Stephan D, Weiher H, Schmidt-Wolf IGH. CIK cells and HDAC inhibitors in Multiple Myeloma. Int J Mol Sci. 2017;18(5):945. https:\/\/doi.org\/10.3390\/ijms18050945.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1724_CR9","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3390\/cancers14102348","volume":"14","author":"IF Coira","year":"2022","unstructured":"Coira IF, Rinc\u00f3n R, Cuendet M. The Multiple Myeloma Landscape: Epigenetics and non-coding RNAs. Cancers (Basel). 2022;14(10):2348. https:\/\/doi.org\/10.3390\/cancers14102348.","journal-title":"Cancers (Basel)"},{"key":"1724_CR10","doi-asserted-by":"publisher","first-page":"1160342","DOI":"10.3389\/fonc.2023.1160342","volume":"13","author":"MQ Lu","year":"2023","unstructured":"Lu MQ, He YQ, Wu Y, Zhou HX, Jian Y, Gao W, Bao L, Chen WM. Identification of aberrantly expressed lncRNAs and ceRNA networks in Multiple Myeloma: a combined high-throughput sequencing and microarray analysis. Front Oncol. 2023;13:1160342. https:\/\/doi.org\/10.3389\/fonc.2023.1160342.","journal-title":"Front Oncol"},{"issue":"1","key":"1724_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/cells12010096","volume":"12","author":"Y Niazi","year":"2022","unstructured":"Niazi Y, Paramasivam N, Blocka J, Kumar A, Huhn S, Schlesner M, Weinhold N, Sijmons R, De Jong M, Durie B, Goldschmidt H, Hemminki K, F\u00f6rsti A. Investigation of Rare non-coding variants in familial Multiple Myeloma. Cells. 2022;12(1):96. https:\/\/doi.org\/10.3390\/cells12010096.","journal-title":"Cells"},{"key":"1724_CR12","doi-asserted-by":"publisher","first-page":"1155177","DOI":"10.3389\/fnmol.2023.1155177","volume":"16","author":"A Sharma","year":"2023","unstructured":"Sharma A, W\u00fcllner U, Schmidt-Wolf IGH, Maciaczyk J. Marginalizing the genomic architecture to identify crosstalk across cancer and neurodegeneration. Front Mol Neurosci. 2023;16:1155177. https:\/\/doi.org\/10.3389\/fnmol.2023.1155177.","journal-title":"Front Mol Neurosci"},{"key":"1724_CR13","doi-asserted-by":"publisher","first-page":"576946","DOI":"10.3389\/fcell.2020.576946","volume":"8","author":"G Li","year":"2020","unstructured":"Li G, Tian Y, Zhu WG. The roles of histone deacetylases and their inhibitors in Cancer Therapy. Front Cell Dev Biol. 2020;8:576946. https:\/\/doi.org\/10.3389\/fcell.2020.576946.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"1724_CR14","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","volume":"13","author":"T Liang","year":"2023","unstructured":"Liang T, Wang F, Elhassan RM, Cheng Y, Tang X, Chen W, Fang H, Hou X. Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm Sin B. 2023;13(6):2425\u201363. https:\/\/doi.org\/10.1016\/j.apsb.2023.02.007.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"1724_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13046-020-01622-x","volume":"39","author":"K Grillone","year":"2020","unstructured":"Grillone K, Riillo C, Scionti F, Rocca R, Tradigo G, Guzzi PH, Alcaro S, Di Martino MT, Tagliaferri P, Tassone P. Non-coding RNAs in cancer: platforms and strategies for investigating the genomic dark matter. J Exp Clin Cancer Res. 2020;39(1):117. https:\/\/doi.org\/10.1186\/s13046-020-01622-x.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01724-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01724-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01724-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T16:20:06Z","timestamp":1700238006000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01724-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1724"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01724-3","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]},"assertion":[{"value":"23 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}